NEWS
PRESS CENTER
2023
2023-07-05
- In May, Received IND approval for Phase I/II study of LAE102 from FDA in the United States
- In June, Listed on the Main Board of the HKEX
- In Sep, Included as a constituent of the Hang Seng Composite Index, and listed in the Stock Connect
Recommendation
-
2024-11-20Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of ObesityMore -
2024-06-26Laekna Announces First Subject Dosed in Phase I Clinical Trial of LAE102 (a monoclonal antibody against ActRIIA) in China for The Treatment of ObesityMore
RSS Feeds
If you want to know more about Laekna, please fill in the form below and sign up for emails:
Follow us on Linkedin
Copyright © Laekna Therapeutics, All Rights Reserved. 沪ICP备17047795号 Privacy Policy
